Predicting liver-related serious adverse events in patients with primary biliary cholangitis-related cirrhosis treated with obeticholic acid

Liver Int. 2022 Nov;42(11):2356-2359. doi: 10.1111/liv.15379.
No abstract available

Publication types

  • Editorial
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Chenodeoxycholic Acid / adverse effects
  • Chenodeoxycholic Acid / analogs & derivatives
  • Cholangitis* / chemically induced
  • Cholangitis* / drug therapy
  • Humans
  • Liver Cirrhosis, Biliary* / complications
  • Liver Cirrhosis, Biliary* / drug therapy
  • Ursodeoxycholic Acid / therapeutic use

Substances

  • obeticholic acid
  • Chenodeoxycholic Acid
  • Ursodeoxycholic Acid